Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

ARYD

Arya Sciences Acquisition Corp IV

Apr 25 • 04:00PM ET

11.33

Dollar change 0.00
Percentage change 0.00	%

Financial • Shell Companies • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.28	Insider Own	55.60%	Shs Outstand	4.19M	Perf Week	0.27%
Market Cap	85.43M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.35M	Perf Month	0.80%
Income	-2.13M	PEG	-	EPS next Q	-	Inst Own	61.15%	Short Float	0.02%	Perf Quarter	4.33%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-1.05%	Short Ratio	0.01	Perf Half Y	7.91%
Book/sh	3.24	P/B	3.50	EPS next Y	-	ROA	-2.22%	Short Interest	0.00M	Perf Year	15.26%
Cash/sh	0.00	P/C	4271.41	EPS next 5Y	-	ROE	-2.53%	52W Range	10.41 - 11.39	Perf YTD	3.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-8.31%	52W High	-0.53%	Beta	-0.01
Dividend TTM	-	Quick Ratio	0.01	Sales past 5Y	0.00%	Gross Margin	-	52W Low	8.84%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	0.01	EPS Y/Y TTM	-602.34%	Oper. Margin	0.00%	RSI (14)	59.84	Volatility	0.18% 0.14%
Employees	3	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-214.96%	Payout	-	Rel Volume	0.00	Prev Close	11.33
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	53.98K	Price	11.33
SMA20	0.36%	SMA50	0.94%	SMA200	6.21%	Trades		Volume	0	Change	0.00%

Feb-14-24 06:06AM	Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies (PR Newswire)
Nov-13-23 02:46PM	Farallon Capital: A Global and Diversified Hedge Fund and its Top Stock Picks (Insider Monkey)
Feb-24-22 07:00AM	ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus Gene Therapy Business Due to Market Conditions (GlobeNewswire)
Nov-30-21 09:36AM	Moore Kuehn Encourages KOR, DISCA, FTSI, and ARYD Investors to Contact Law Firm (PR Newswire)
Nov-09-21 05:47PM	SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigation of EJF, HTPA, ARYD, and ADER Mergers (GlobeNewswire)
06:00PM	Loading…
Oct-06-21 06:00PM	NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith Reminds Investors of Investigations Related to the Following Companies: ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD), Poema Global Holdings Corp. (NASDAQ:PPGH), VPC Impact Acquisition Holdings III, Inc. (NYSE:VPCC) (ACCESSWIRE)
09:25AM	Moore Kuehn Encourages NOTV, ARYD, XLRN, and TGP Investors to Contact Law Firm (GlobeNewswire)
Oct-01-21 12:01PM	SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of ARYA Sciences Acquisition Corp. IV Merger (GlobeNewswire)
Sep-30-21 08:18AM	Amicus stock is up 5%, the day after announcing plans to sell its gene therapy business (MarketWatch)
Sep-29-21 05:30PM	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of ARYA Sciences Acquisition Corp IV (Nasdaq - ARYD) (ACCESSWIRE)
06:30AM	Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: Caritas Therapeutics (GlobeNewswire)

ARYA Sciences Acquisition Corp. IV operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on August 24, 2020 by Joseph Eric Edelman, Adam Stone, Michael R. Altman, and Poukalov Konstantin and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARYD

Arya Sciences Acquisition Corp IV

Upgrade your FINVIZ experience